Limited data exist on the effect of intravenous immunoglobulin (IVIg) on anti-HLA antibodies as determined by solid-phase assays. We reviewed our experience treating sensitized wait-listed kidney transplant recipients with IVIg as a method for desensitization and report our results utilizing Luminex single antigen (LSA) bead assay to quantify antibody reactivity (MFI). Fifteen patients with a cPRA > 40% received 2 g/kg IVIg per month for four months or until transplanted. LSA testing was performed before and after IVIg. Median MFI for anti-class I antibodies fell in 11 (73%) and increased in 4 (27%) patients after IVIg. Similar significant changes in MFI for anti-class II antibodies were observed in 10 patients (66%). Administration of IVIg was associated with a modest decrease in reactivity to both class I and II HLA antigens (median MFI change 493 and 1110, respectively; p < 0.0001) but did not significantly alter mean cPRA (85% before IVIg vs. 80% after IVIg; p = 0.1). Our data suggest a smaller effect of IVIg on HLA antibody reactivity than previously described, leading us to question how best to measure the efficacy of a desensitization protocol in current practice.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3381356 | PMC |
| http://dx.doi.org/10.1111/j.1399-0012.2012.01657.x | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Practical insights into bispecific antibody therapy in multiple myeloma.
Expert Rev Anticancer Ther
December 2024
Department of Pharmacy, University of California Davis Medical Center, Sacramento, CA, USA.
Introduction: The rise of recent novel therapies teclistamab, elranatamab, and talquetamab for the treatment of relapsed/refractory multiple myeloma (RRMM) is a rapidly evolving area with significant clinical implications that require exploration and evaluation.
Areas Covered: The current review highlights the clinical trial data, safety endpoints, and practical administration considerations for the bispecific therapies currently used in multiple myeloma. This article reviewed the efficacy and safety results between the three different bispecifics, and the differences in dosing and monitoring requirements.
Co-Existent Central and Peripheral Demyelination: Related or Coincidental?
Neurol Int
December 2024
Department of Neurology, University of Texas Medical Branch, Galveston, TX 77555, USA.
Background: Hereditary Sensory Motor Neuropathy (HSMN) 1A and Multiple Sclerosis (MS) are distinct demyelinating disorders affecting the peripheral and central nervous systems, respectively. We present a case of simultaneous occurrence of both conditions, exploring the clinical presentation, diagnostic workup, and potential interplay between these diseases. Case presentation and clinical approach: A 49-year-old male with a history of optic neuritis presented with progressive numbness, weakness, and sensory loss in all extremities over four years.
View Article and Find Full Text PDF[Treatment Strategies for Chronic Inflammatory Demyelinating Polyneuropathy].
Brain Nerve
January 2025
Department of Neurology, Dokkyo Medical University.
Three main treatments are available for management of chronic inflammatory demyelinating polyneuropathy (CIDP). Both induction and maintenance therapies should be considered for treatment of CIDP. Plasma exchange and intravenous immunoglobulin therapy are effective as induction treatments for CIDP, and corticosteroid administration, such as daily oral or pulse therapies, may be effective for both induction and maintenance.
View Article and Find Full Text PDFSerum glycobiomarkers for chronic inflammatory demyelinating polyneuropathy.
Eur J Neurol
January 2025
Department of Neurology, Nagoya University Graduate School of Medicine, Nagoya, Aichi, Japan.
Article Synopsis
- The study analyzed glycan biomarkers in serum to understand their relationship with chronic inflammatory demyelinating polyneuropathy (CIDP) and treatment effects.
- Significant differences were found in N-glycan levels, particularly lower sialylated N-glycans in CIDP patients compared to healthy controls, while O-glycan levels remained unchanged.
- Lower sialylated N-glycan levels may indicate therapeutic resistance and could serve as a potential biomarker for CIDP’s pathophysiology.
ROHHAD NET in Retrospect: Key Lessons Learned from Five Cases.
Indian J Pediatr
December 2024
Division of Endocrinology, Department of Pediatrics, All India Institute of Medical Sciences, New Delhi, 110029, India.
Objectives: To present cases of rapid onset obesity with hypothalamic dysfunction, hypoventilation, and autonomic dysregulation (ROHHAD) and discuss management insights.
Methods: Case records of patients fulfilling the criteria for ROHHAD and presenting to the Pediatric Endocrinology Division of All India Institute of Medical Sciences, New Delhi, between July 2019 and June 2024 were reviewed for clinical features, treatments, and outcomes.
Results: Five patients (4 boys, 1 girl) presented at a median age of 4 y (range 3.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!